Royalty Amounts. Abrika shall pay to Corium the following royalties during the Term of this Agreement: I
A. [*] of the Net Sales Price received by Abrika from the sale of the Licensed Product in the United States so long as Corium is manufacturing and supplying the Licensed Product to Abrika pursuant to the terms of the Supply Agreement; or
B. [*] of the Net Sales Price received by Abrika from the sale of the Licensed Product in the United States if: (i) Corium is not manufacturing and supplying the Licensed Product to Abrika pursuant to the terms of the Supply Agreement, and (ii) Corium has developed Project IP which is being actively utilized in connection with the Licensed Product; or
C. [*] of the Net Sales Price received by Abrika from the sale of the Licensed Product in the United States if: (i) Corium is not manufacturing and supplying the Licensed Product to Abrika pursuant to the terms of the Supply Agreement, and (ii) Corium has not developed Project IP which is being actively utilized in connection with the Licensed Product.
D. For all sales of the Licensed Product outside the United States, the Parties shall determine the amount of royalties to be paid to Corium on a case-by-case basis. The Parties agree to negotiate in good faith to determine a value for such royalties which accurately reflects the contribution of each Party towards the realization of such sales of the Licensed Product.
Royalty Amounts. During the Royalty Term for each Sole Development Product commercialized by the Developing Party under ARTICLE VI, the Developing Party will pay the Discontinuing Party a royalty on Net Sales of such Sole Development Product (except to the extent otherwise provided under Section 7.5(b)) at the following rates:
(i) if, as of the date the Opt-Out Notice is delivered, the first patient has not yet been enrolled in a Phase II Study of such Sole Development Product, such royalty shall be [*] percent ([*%]) with respect to Net Sales of Sole Development Products for which Angiotech is the Developing Party, and no royalty with respect to Net Sales of Sole Development Products for which Athersys is the Developing Party;
(ii) if, as of the date the Opt-Out Notice is delivered, the first patient has been enrolled in a Phase II Study of such Sole Development Product Table of Contents but the first patient has not yet been enrolled in a Phase III Study of such Sole Development Product, such royalty shall be [*] percent ([*%]) with respect to Net Sales of Sole Development Products for which Angiotech is the Developing Party, and [*] percent ([*%]) with respect to Net Sales of Sole Development Products for which Athersys is the Developing Party; and
(iii) if, as of the date the Opt-Out Notice is delivered, the first patient has been enrolled in a Phase III Study for such Sole Development Product and thereafter, such royalty shall be [*] percent ([*%]) with respect to Net Sales of Sole Development Products regardless of which Party is the Developing Party; provided, however, that if it is unclear whether a clinical trial is in a particular phase, the actual phase of such clinical trial shall be determined by reference to the next following clinical trial for such Sole Development Product (e.g., a Phase I/II clinical trial would be considered a Phase II Study if, following completion of such trial, the Developing Party commences a Phase III Study of such Sole Development Product). If (xi) Angiotech is the Discontinuing Party and has elected to decline payment of the Phase I Milestone Fee pursuant to Section 2.4(b), and (xii) Athersys has elected to receive a greater share of Profits pursuant to Section 2.4(b)(ii), then the royalty rate payable to Angiotech pursuant to clause (ii) above shall be [*] percent [*%] and the royalty rate payable to Angiotech pursuant to clause (iii) above shall be [*] percent [*%]. The royalties payable pursuant to this Section 7.5(a) shall not ...
Royalty Amounts. Subject to Section 4.2(a), during the Royalty Period, Licensee shall pay to Licensor, within forty-five (45) days following each calendar quarter in a year beginning April 1 and ending March 31 (a “Contract Year”) or portion thereof during the Term, the following royalty fee (“Royalty Fee”): Less than Ten Million Dollars ($10,000,000) Zero percent (0%) of Net Sales Between Ten Million Dollars ($10,000,000) and Twenty Million Dollars ($20,000,000) Seven percent (7%) of Net Sales More than Twenty Million Dollars ($20,000,000) Ten percent (10%) of Net Sales A Royalty Fee calculation example is attached hereto as Exhibit D.
Royalty Amounts. Sublicensee shall pay to Sublicensor earned royalties as follows:
(i) a royalty of *** of the first *** of Net Sales for each calendar year under this Agreement;
(ii) a royalty of *** of Net Sales over *** for each calendar year under this Agreement;
(iii) a royalty of *** of Net Sales over *** for each calendar year under this Agreement; and
(iv) a royalty of *** of Net Sales over *** for each calendar year under this Agreement. The above-listed royalty rates shall be increased to *** respectively, upon issuance of a valid United States patent based on and having substantially the same claims as presently pending United States Patent Application Serial No. 07/397707, and such increased royalty rates shall be applicable to royalty payments which accrue on or after the issue date of such patent. Royalty payments shall accrue under this Agreement when Transgenic Products or Transgenic Contract Services are sold or leased by Sublicensee (and/or any Affiliates of Sublicensee) to a third party, or, if Transgenic Products or Transgenic Contract Services are not sold or leased but are the subject of a sublicense or other such agreement between Sublicensee (and/or any Affiliates of Sublicensee) and a third party, when any royalties or other such revenues are received by Sublicensee or any of its Affiliates for such products.
Royalty Amounts. The royalty shall be U.S. [***]for each Royalty Product sold.
Royalty Amounts. In consideration of the license granted herein and for the Term of this License Agreement, Licensee will pay to Institution, in the manner designated in this License Agreement, as earned royalty, the amounts set out in Schedule “B” attached to this License Agreement.
Royalty Amounts. In the case of Products distributed through the Release Point of Sale Network, Distributor will pay Vendor a royalty in accordance with the Point of Sale Network Royalty Schedule set forth in Exhibit C and, in the case of the distribution of Products through the Publisher Direct Program, Distributor will pay Vendor a royalty in accordance with the Publisher Direct Royalty Schedule set forth in Exhibit C (collectively referred to herein as the "Royalty" or "Royalties"), provided that no Royalty shall be owed for: (a) copies of the Products [***] = CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. returned to Distributor for refund in accordance with the End User License Agreement or Section 3.2, or because of defects or errors, regardless of source; or (b) chargeback transactions (except as expressly provided in Section 6.2 below).
Royalty Amounts. Subject to the terms and conditions of this Agreement, in consideration of the rights and licenses granted herein, the Licensee shall pay to the Licensor a royalty equal to [**Confidential Treatment Requested] percent ([**Confidential Treatment Requested]%) of Gross Sales (collectively, the “Royalty”).
Royalty Amounts. Akebia shall pay Licensee a nonrefundable and noncreditable royalty equivalent to the sum of (i) [**] of all Licensed Products sold by Akebia to Licensee, (ii) Akebia’s share of the Profit ([**]%) on Licensed Products sold to the Licensee Supply Group, and (iii) Akebia’s net sales of the Licensed Product outside of the Licensee Supply Group in the Territory (the sum of (i) through (iii) referred to herein as the “Akebia Licensed Product Revenue”), during each calendar quarter , multiplied by the applicable incremental royalty rates set forth in Table A below (the “Royalty Payments”). The Royalty Payments shall be made during each calendar quarter from July 1, 2025 until the expiry of the Royalty Term (as defined below). For the purpose of calculating the Akebia Licensed Product Revenue above, Akebia’s net sales of the Licensed Product outside of the Licensee Supply Group shall be calculated in the same manner as Licensee calculates its own Net Sales under Section 1.85 of the License Agreement. For avoidance of any doubt, all sales made by Akebia to the Licensee Supply Group following expiry or termination of the License Agreement shall be deemed net sales of Akebia for the calculation of the Licensed Product Revenue.
Royalty Amounts. Licensee will pay Akebia nonrefundable and noncreditable royalties based on Net Sales of the Licensed Product in the Territory during the Royalty Term at the applicable incremental royalty rates set forth in Table 9.3.1 for Net Sales of the Licensed Product (“Royalty Payments”). Net Sales for all countries will be aggregated for purposes of calculating the applicable royalty tier for Net Sales. >€[**] 30%
